Supplementary Figure S5 from Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Year: 2024
Type: supplementary-materials
Abstract: Association between cfDNA concentration and residual cancer burden (RCB). CfDNA concentration was measured in the plasma of patients with A. hormone receptor-positive HER2-negative (HR+HER2-) and B. triple-negative breast cancer (TNBC). Blood was collected at pretreatment (T0), 3 weeks after treatment initiation (T1), 12 weeks after treatment initiation between paclitaxel-based treatment and anthracycline regimens (T2), and after neoadjuvant chemotherapy (NAC) before surgery (T3). RCB was divided into 4 classes: RCB-0, equivalent to pathologic complete response, and RCB-I, -II, -III, representing limited, moderate, and extensive residual cancer after NAC, respectively. Pairwise P values were calculated using the Wilcoxon rank sum test, with Bonferroni correction to adjust for multiple comparisons.
Authors: Mark Jesus M. Magbanua, Ziad Ahmed, Rosalyn W. Sayaman, Lamorna Brown Swigart, Gillian L. Hirst, Christina Yau, Denise M. Wolf, Wen Li, Amy L. Delson, Jane Perlmutter, Paula Pohlmann, W. Fraser Symmans, Douglas Yee, Nola M. Hylton, Laura J. Esserman, Angela M. DeMichele, Hope S. Rugo, Laura J. van 't Veer
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4399298247